[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NEXTGEN Bioscience\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100524139","phase-2-safety-and-efficacy-of-oral-nxc-736-in-adult-participants-with-moderate-and-severe-alopecia-areata-100524139",false,"NCT06104839","Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata","Inclusion Criteria:\n\n* Men or women between ≥19 and ≤65 years of age at the time of informed consent\n* Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \\\u003C 95% at Screening and Day 1\u002FBaseline\n* Current episode of hair loss for ≥6 months but \\\u003C8 years\n* Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator\n* Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study\n\nExclusion Criteria:\n\n* Participants with the following medical history confirmed during screening:\n\n  * ohter Types of alopecia other than alopecia areata (such as cicatricial\u002Fscarring alopecia \\[including central centrifugal cicatricial alopecia\\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)\n* Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment\n* Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors","ALL","19 Years","65 Years",{"count":20,"type":21},73,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).",[27],"Alopecia Areata","RECRUITING","2026-04-09",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":32},"2024-09-01",{"date":36,"type":21},"2027-01-31",{"name":38,"class":39},"NEXTGEN Bioscience","INDUSTRY",2,""]